Itraisdin

Itraconazole, the active ingredient in Itraisdin, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including dermatophytosis, candidiasis, blastomycosis, histoplasmosis, sporotrichosis and, off‑label, aspergillosis, in adult patients. It is indicated for both superficial and deep mycotic diseases and is commonly prescribed when first‑line agents are insufficient.

GNH USA supplies Itraisdin as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with reliable bulk and parcel shipments.

Itraisdin (itraconazole) is an azole antifungal used to treat infections caused by susceptible fungi.

Dermatophytosis: reduces fungal growth and clears skin lesions. Candidiasis: eradicates yeast infection in oral, esophageal and systemic sites. Blastomycosis: eliminates Blastomyces organisms and resolves pulmonary involvement. Histoplasmosis: clears Histoplasma infection and prevents dissemination. Sporotrichosis: treats skin and subcutaneous infection caused by Sporothrix species.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: skin irritation or mild erythema. - Diarrhea: loose stools occasionally reported. - Taste alteration: temporary change in taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Cardiac arrhythmias: QT interval prolongation leading to irregular heartbeat. - Hepatic failure: rare but potentially life‑threatening liver injury. - Visual disturbances: blurred vision or photophobia.

Before initiating therapy, consider the following precautions: - Liver function monitoring: obtain baseline and periodic liver enzyme tests. - Drug interaction review: assess concomitant medications for CYP3A4 interactions. - Pregnancy safety: avoid use unless benefits outweigh potential risks. - Breastfeeding: discontinue if nursing or assess infant risk. - Renal impairment: adjust dose if severe kidney dysfunction is present. - Store at ambient temperature: keep in the original container, protect from moisture.

Itraconazole may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reducing itraconazole exposure. - Ketoconazole: additive hepatotoxicity risk when combined. - Sildenafil: increased plasma levels may cause hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise itraconazole concentrations. - Statins (e.g., simvastatin): heightened risk of myopathy. - Warfarin: potential increase in INR, requiring closer anticoagulation monitoring.